74 related articles for article (PubMed ID: 12555063)
1. Oncogenic effect of delta deletion in v-Jun does not result from uncoupling Jun from JNK signaling.
Sprowles A; Wisdom R
Oncogene; 2003 Jan; 22(4):498-506. PubMed ID: 12555063
[TBL] [Abstract][Full Text] [Related]
2. Differential targeting of the stress mitogen-activated protein kinases to the c-Jun dimerization protein 2.
Katz S; Aronheim A
Biochem J; 2002 Dec; 368(Pt 3):939-45. PubMed ID: 12225289
[TBL] [Abstract][Full Text] [Related]
3. Directed mutation of the basic domain of v-Jun alters DNA binding specificity and abolishes its oncogenic activity in chicken embryo fibroblasts.
Basso J; Briggs J; Findlay C; Bos T
Oncogene; 2000 Oct; 19(42):4876-85. PubMed ID: 11039905
[TBL] [Abstract][Full Text] [Related]
4. Effector peptides from glutathione-S-transferase-pi affect the activation of jun by jun-N-terminal kinase.
Adler V; Pincus MR
Ann Clin Lab Sci; 2004; 34(1):35-46. PubMed ID: 15038666
[TBL] [Abstract][Full Text] [Related]
5. Efficient induction of fibrosarcomas by v-jun requires mutations in the DNA binding region and the transactivation domain.
Morgan IM; Håvarstein LS; Wong WY; Luu P; Vogt PK
Oncogene; 1994 Oct; 9(10):2793-7. PubMed ID: 8084584
[TBL] [Abstract][Full Text] [Related]
6. TOJ3, a target of the v-Jun transcription factor, encodes a protein with transforming activity related to human microspherule protein 1 (MCRS1).
Bader AG; Schneider ML; Bister K; Hartl M
Oncogene; 2001 Nov; 20(51):7524-35. PubMed ID: 11709724
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Delta12,14-prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor-gamma-independent mechanism.
Grau R; Iñiguez MA; Fresno M
Cancer Res; 2004 Aug; 64(15):5162-71. PubMed ID: 15289320
[TBL] [Abstract][Full Text] [Related]
8. Amino acid substitutions modulate the effect of Jun on transformation, transcriptional activation and DNA replication.
Morgan IM; Asano M; Håvarstein LS; Ishikawa H; Hiiragi T; Ito Y; Vogt PK
Oncogene; 1993 May; 8(5):1135-40. PubMed ID: 8479738
[TBL] [Abstract][Full Text] [Related]
9. A new c-Jun N-terminal kinase (JNK)-interacting protein, Sab (SH3BP5), associates with mitochondria.
Wiltshire C; Matsushita M; Tsukada S; Gillespie DA; May GH
Biochem J; 2002 Nov; 367(Pt 3):577-85. PubMed ID: 12167088
[TBL] [Abstract][Full Text] [Related]
10. c-Jun controls the efficiency of MAP kinase signaling by transcriptional repression of MAP kinase phosphatases.
Sprowles A; Robinson D; Wu YM; Kung HJ; Wisdom R
Exp Cell Res; 2005 Aug; 308(2):459-68. PubMed ID: 15950217
[TBL] [Abstract][Full Text] [Related]
11. JNK phosphorylation relieves HDAC3-dependent suppression of the transcriptional activity of c-Jun.
Weiss C; Schneider S; Wagner EF; Zhang X; Seto E; Bohmann D
EMBO J; 2003 Jul; 22(14):3686-95. PubMed ID: 12853483
[TBL] [Abstract][Full Text] [Related]
12. PP2A regulates upstream members of the c-jun N-terminal kinase mitogen-activated protein kinase signaling pathway.
Zhao B; Sun L; Haas M; Denenberg AG; Wong HR; Shanley TP
Shock; 2008 Feb; 29(2):181-8. PubMed ID: 17693927
[TBL] [Abstract][Full Text] [Related]
13. Activation of DNA methyltransferase 1 by EBV LMP1 Involves c-Jun NH(2)-terminal kinase signaling.
Tsai CL; Li HP; Lu YJ; Hsueh C; Liang Y; Chen CL; Tsao SW; Tse KP; Yu JS; Chang YS
Cancer Res; 2006 Dec; 66(24):11668-76. PubMed ID: 17178861
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional activation by the v-Jun oncoprotein is independent of positive regulatory phosphorylation.
Black EJ; Catling AD; Woodgett JR; Kilbey A; Gillespie DA
Oncogene; 1994 Aug; 9(8):2363-8. PubMed ID: 8036019
[TBL] [Abstract][Full Text] [Related]
15. Functional interactions of Raf and MEK with Jun-N-terminal kinase (JNK) result in a positive feedback loop on the oncogenic Ras signaling pathway.
Adler V; Qu Y; Smith SJ; Izotova L; Pestka S; Kung HF; Lin M; Friedman FK; Chie L; Chung D; Boutjdir M; Pincus MR
Biochemistry; 2005 Aug; 44(32):10784-95. PubMed ID: 16086581
[TBL] [Abstract][Full Text] [Related]
16. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.
Elsässer A; Franzen M; Kohlmann A; Weisser M; Schnittger S; Schoch C; Reddy VA; Burel S; Zhang DE; Ueffing M; Tenen DG; Hiddemann W; Behre G
Oncogene; 2003 Aug; 22(36):5646-57. PubMed ID: 12944913
[TBL] [Abstract][Full Text] [Related]
17. A peptide fragment of ependymin neurotrophic factor uses protein kinase C and the mitogen-activated protein kinase pathway to activate c-Jun N-terminal kinase and a functional AP-1 containing c-Jun and c-Fos proteins in mouse NB2a cells.
Adams DS; Hasson B; Boyer-Boiteau A; El-Khishin A; Shashoua VE
J Neurosci Res; 2003 May; 72(3):405-16. PubMed ID: 12692907
[TBL] [Abstract][Full Text] [Related]
18. The BRCA2 activation domain associates with and is phosphorylated by a cellular protein kinase.
Milner J; Fuks F; Hughes-Davies L; Kouzarides T
Oncogene; 2000 Sep; 19(38):4441-5. PubMed ID: 10980621
[TBL] [Abstract][Full Text] [Related]
19. Phosphatidylinositol-3 kinase is distinctively required for mu-, but not kappa-opioid receptor-induced activation of c-Jun N-terminal kinase.
Kam AY; Chan AS; Wong YH
J Neurochem; 2004 Apr; 89(2):391-402. PubMed ID: 15056283
[TBL] [Abstract][Full Text] [Related]
20. An oncogenic mutation uncouples the v-Jun oncoprotein from positive regulation by the SAPK/JNK pathway in vivo.
May GH; Funk M; Black EJ; Clark W; Hussain S; Woodgett JR; Gillespie DA
Curr Biol; 1998 Jan; 8(2):117-20. PubMed ID: 9427647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
